PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsStomach neoplasms
MeSH D013274 - stomach neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D005770:Gastrointestinal neoplasms
29 Companies
6 Drugs
$
Success rate
D013272:Stomach diseases
2 Companies
3 Drugs
$
Success rate
D013274: 
Stomach neoplasms
71 Companies
15 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaFluorouracil Adrucil  1991-10-18   
Capecitabine Capecitabine Teva  2012-04-20   
Docetaxel Docetaxel  2015-09-16   
Docetaxel Docetaxel Teva  2010-01-26   
Docetaxel Docetaxel Teva Pharma  2011-01-21   
Fluorouracil Fluorouracil  2000-01-27   
Ifosfamide, Mesna Ifosfamide/mesna  2002-02-26   
Cisplatin Cisplatin  2000-05-16   
Irinotecan Irinotecan  2008-02-27   
Novast LaboratoriesFluorouracil Fluorouracil  2019-12-12   
Irinotecan Irinotecan  2017-05-26   
Taro PharmaceuticalFluorouracil Fluorouracil  2003-11-05   
IngenusDocetaxel Docetaxel 2036-03-14 2022-11-22   
MylanDocetaxel Docetaxel  2023-05-11   
Docetaxel Docetaxel Mylan  2012-01-31   
Cisplatin Cisplatin  2012-04-18   
Methotrexate Methotrexate  1992-05-15   
Rising PharmaceuticalsFluorouracil Fluorouracil  2015-04-20   
Methotrexate Methotrexate  2012-03-29   
RocheTrastuzumab Herceptin  2000-08-28 $2,044.082 M Q4/22-Q3/23 
SandozDocetaxel Docetaxel  2011-06-29   
Fluorouracil Fluorouracil  2011-05-02   
Trastuzumab Herwenda  2023-11-15   
Irinotecan Irinotecan  2008-02-27   
SanofiDocetaxel Taxotere  1996-05-14   
Bausch Health CompaniesFluorouracil Carac  2000-10-27   
Fluorouracil Efudex  1982-01-01   
1
2
3
4
5
6
...
8
>
Clinical Trials
Historical Success Rate
Phase 1
74%
103/139
Phase 2
30%
57/192
Phase 3
41%
42/103
Approved: 16Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Capecitabine,
Cisplatin,
Docetaxel,
Fluorouracil
Mylan
Docetaxel
Roche
Trastuzumab,
Trastuzumab deruxtecan,
Trastuzumab emtansine,
Tiragolumab,
Onartuzumab,
Lenograstim,
Doconexent,
Molgramostim,
Aspartame,
Bevifimod,
Nepidermin,
Polyglycolic acid,
Globulin, immune,
Krestin,
Anthracycline,
Aminoglycoside,
Doxorubin,
Lactams,
Folinoral,
Hydroxydaunomycin,
Docetaxol,
Fluoropyrimidine,
Taxane
Sanofi
Docetaxel,
Gilvetmab,
Tusamitamab ravtansine,
Lenograstim,
Molgramostim,
ALOMFILIMAB,
Aspartame,
Bevifimod,
Levoglucose,
Nepidermin,
Polyglycolic acid,
Globulin, immune,
Krestin,
Mk3475,
Folinoral,
Histone-arginine methyltransferase carm1,
Docetaxol,
Fluoropyrimidine,
Taxane
Bausch Health Companies
Fluorouracil
Pfizer
Trastuzumab,
Trastuzumab deruxtecan,
Trastuzumab emtansine,
Docetaxel,
Irinotecan,
Irinotecan hydrochloride,
Irinotecan sucrosofate,
Sasanlimab,
Gilvetmab,
Spartalizumab,
Edotecarin,
Bevifimod,
Nadide,
Polyglycolic acid,
Globulin, immune,
Ag013736,
Amchafibrin,
Folinoral,
Histone-arginine methyltransferase carm1,
Surlorian,
Docetaxol,
Taxane,
Pf00299804
Eli Lilly
Ramucirumab,
Gilvetmab,
Aglatimagene besadenovec,
Doconexent,
Bevifimod,
EMIBETUZUMAB,
LITRONESIB,
Nepidermin,
Polyglycolic acid,
Telbermin,
Globulin, immune,
Docetaxol,
Fluoropyrimidine,
Taxane
1
2
3
4
5
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use